List view / Grid view
1 December 2014 | By ABIVAX
ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, announced the successful completion of its Phase 1 first-in-man study of ABX464, which has been designed to potentially deliver a number of important clinical benefits when treating patients with HIV.,,
21 November 2014 | By The Institute of Cancer Research
Professor Paul Workman sets out his vision for cancer drug discovery as he is appointed Chief Executive of The Institute of Cancer Research, London
19 November 2014 | By Nosopharm
These high-profile experts will help with the quick and safe launch of the preclinical development program for a new class of antibiotics...
13 November 2014 | By Bristol-Myers Squibb
The Partnering for Cure faculty of experts announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV)...
13 November 2014 | By Amgen
Thirteen presentations include new analyses of PCSK9 inhibitor at upcoming American Heart Association Scientific sessions...
Neutrons, electrically neutral particles found within the nucleus of the atom, are coming into their own in the exploration of new ways to get drugs to their targets. Neutron techniques are being used to investigate innovative new approaches to drug delivery that could increase the effectiveness of treatments, improve the…
The use of monoclonal antibodies and antibody-based molecules as therapeutics to treat patients suffering with severe disease has become a major success story. Due to the exquisite specificity with which they interact with their antigen and the fact that their large binding surface can intervene at sites and targets not…
24 July 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead’s investigational drug tenofovir alafenamide...
12 June 2014 | By GlaxoSmithKline
ViiV Healthcare announced that they have entered into an agreement with Janssen R&D Ireland Ltd for the development and commercialisation of a single-tablet combining dolutegravir (Tivicay®) and Janssen’s non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant®1)...
6 June 2014 | By Merck
MSD announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK...
13 May 2014 | By Johnson & Johnson
Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson’s wider efforts to improve public health worldwide...
Chemokines orchestrate leukocyte trafficking in the immune system, but unregulated or inappropriate chemokine activity plays a key role in many inflammatory, allergic and autoimmune diseases as well as metastatic tumour progression. The chemokine network is comprised of ~50 distinct ligands that specifically bind and activate a family of 20 G…
30 April 2014 | By Johnson & Johnson
Johnson & Johnson announced that its affiliate Janssen Pharmaceutica NV has entered into a novel collaboration with the Stichting International Dispensary Association...
6 March 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company presented 24-week Phase IIb data that demonstrated similar response rates for its investigational compound...
